间质性肺疾病合并慢性阻塞性肺疾病的研究进展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

林庄恒 ,  柴燕玲

昆明医科大学第二附属医院呼吸与危重症医学科二病区（云南昆明 650000）;

Corresponding author：

柴燕玲, Email: chai_yanlin@126.com

Keywords：

DOI：

10.7507/1671-6205.202311035

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

1.	Liu Q, Sun D, Wang Y, et al. Use of machine learning models to predict prognosis of combined pulmonary fibrosis and emphysema in a Chinese population. BMC Pulm Med, 2022, 22(1): 327.
2.	Lee T S, Jin K N, Lee H W, et al. Interstitial lung abnormalities and the clinical course in patients with COPD. Chest, 2021, 159(1): 128-137.
3.	Hoyer N, Thomsen LH, Wille MMW, et al. Increased respiratory morbidity in individuals with interstitial lung abnormalities. BMC Pulm Med, 2020, 20(1): 67.
4.	Wong A W, Liang J, Cottin V, et al. Diagnostic features in combined pulmonary fibrosis and emphysema: a systematic review. Ann Am Thorac Soc, 2020, 17(10): 1333-6.
5.	Sangani R, Ghio A, Culp S, et al. Combined pulmonary fibrosis emphysema: role of cigarette smoking and pulmonary hypertension in a rural cohort. Int J Chron Obstruct Pulmon Dis, 2021, 16: 1873-1885.
6.	Koo BS, Park KY, Lee HJ, et al. Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis. Arthritis Res Ther, 2021, 23(1): 100.
7.	Nemoto M, Nei Y, Bartholmai B, et al. Automated computed tomography quantification of fibrosis predicts prognosis in combined pulmonary fibrosis and emphysema in a real-world setting: a single-centre, retrospective study. Respir Res, 2020, 21(1): 275.
8.	Lee J H, Park H J, Kim S, et al. Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study. BMC Pulm Med, 2023, 23(1): 54.
9.	Lee S H, Park J S, Kim S Y, et al. Clinical features and prognosis of patients with idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis, 2019, 23(6): 678-684.
10.	赵倩, 范亚丽, 马瑞敏, 等. 矽肺合并慢性阻塞性肺疾病患病率和危险因素分析. 中华劳动卫生职业病杂志, 2022, 40(8): 602-606.
11.	石蕊, 刘红梅, 孙志谦, 等. 矽肺并发慢性阻塞性肺疾病的回顾性分析. 中华劳动卫生职业病杂志, 2021, 39(8): 590-593.
12.	Jacob J, Odink A, Brun A L, et al. Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis. Respir Med, 2018, 138: 95-101.
13.	Li L, Yang D C, Chen C H. Metabolic reprogramming: a driver of cigarette smoke-induced inflammatory lung diseases. Free Radic Biol Med, 2021, 163: 392-401.
14.	Cottin V, Selman M, Inoue Y, et al. Syndrome of combined pulmonary fibrosis and emphysema: an official ATS/ERS/JRS/ALAT Research Statement. Am J Respir Crit Care Med, 2022, 206(4): e7-e41.
15.	Sack CS, Doney BC, Podolanczuk AJ, et al. Occupational exposures and subclinical interstitial lung disease. The MESA (Multi-Ethnic Study of Atherosclerosis) Air and Lung Studies. Am J Respir Crit Care Med, 2017, 196(8): 1031-1039.
16.	Arimura-Omori M, Kiyohara C, Yanagihara T, et al. Association between telomere-related polymorphisms and the risk of IPF and COPD as a precursor lesion of lung cancer: findings from the Fukuoka Tobacco-Related Lung Disease (FOLD) Registry. Asian Pac J Cancer Prev, 2020, 21(3): 667-673.
17.	Guzmán-Vargas J, Ambrocio-Ortiz E, Pérez-Rubio G, et al. Differential genomic profile in TERT, DSP, and FAM13A between COPD patients with emphysema, IPF, and CPFE syndrome. Front Med (Lausanne), 2021, 8: 725144.
18.	Ghosh AJ, Hobbs BD, Yun JH, et al. Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Respir Res, 2022, 23(1): 97.
19.	Avci E, Sarvari P, Savai R, et al. Epigenetic mechanisms in parenchymal lung diseases: bystanders or therapeutic targets?. Int J Mol Sci, 2022, 23(1): 546.
20.	Soni DK, Biswas R. Role of non-coding RNAs in post-transcriptional regulation of lung diseases. Front Genet, 2021, 12: 767348.
21.	Kaur G, Maremanda KP, Campos M, et al. Distinct exosomal miRNA profiles from balf and lung tissue of COPD and IPF Patients. Int J Mol Sci, 2021, 22(21): 11830.
22.	Aghali A, Koloko Ngassie ML, Pabelick CM, et al. Cellular senescence in aging lungs and diseases. Cells, 2022, 11(11): 1781.
23.	Ortiz-Zapater E, Signes-Costa J, Montero P, et al. Lung fibrosis and fibrosis in the lungs: is it all about myofibroblasts?. Biomedicines, 2022, 10(6).
24.	Nemoto MMD, Koo CWMD, Ryu JHMD. Diagnosis and treatment of combined pulmonary fibrosis and emphysema in 2022. JAMA, 2022, 328(1): 69-70.
25.	Ogata-Suetsugu S, Hamada N, Tsuda T, et al. Characteristics of tobacco-related lung diseases in Fukuoka Prefecture, Japan: a prospective, multi-institutional, observational study. Respir Investig, 2020, 58(1): 74-80.
26.	Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med, 2011, 364(10): 897-906.
27.	Özmen İ, Yıldırım E, Öztürk M, et al. Pulmonary rehabilitation reduces emergency admission and hospitalization rates of patients with chronic respiratory diseases. Turk Thorac J, 2018, 19(4): 170-175.
28.	Rochester CL, Alison JA, Carlin B, et al. Pulmonary rehabilitation for adults with chronic respiratory disease: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med, 2023, 208(4): e7-e26.
29.	Zhang L, Maitinuer A, Lian Z, et al. Home based pulmonary tele-rehabilitation under telemedicine system for COPD: a cohort study. BMC Pulm Med, 2022, 22(1): 284.
30.	Tomioka H, Mamesaya N, Yamashita S, et al. Combined pulmonary fibrosis and emphysema: effect of pulmonary rehabilitation in comparison with chronic obstructive pulmonary disease. BMJ Open Respir Res, 2016, 3(1): e000099.
31.	Dong F, Zhang Y, Chi F, et al. Clinical efficacy and safety of ICS/LABA in patients with combined idiopathic pulmonary fibrosis and emphysema. Int J Clin Exp Med, 2015, 8(6): 8617-8625.
32.	Choi JY, Song JW, Rhee CK. Chronic obstructive pulmonary disease combined with interstitial lung disease. Tuberc Respir Dis (Seoul), 2022, 85(2): 122-136.
33.	宋庆, 林铃, 李雪杉, 等. 慢性阻塞性肺疾病与干细胞的研究进展. 中国呼吸与危重监护杂志, 2022, 21(10): 745-750.
34.	Huleihel L, Levine M, Rojas M. The potential of cell-based therapy in lung diseases. Expert Opin Biol Ther, 2013, 13(10): 1429-1440.
35.	Cruz FF, Rocco PRM. The potential of mesenchymal stem cell therapy for chronic lung disease. Expert Rev Respir Med, 2020, 14(1): 31-39.
36.	Antunes MA, Abreu SC, Cruz FF, et al. Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema. Respir Res, 2014, 15(1): 118.
37.	Antoniou KM, Karagiannis K, Tsitoura E, et al. Clinical applications of mesenchymal stem cells in chronic lung diseases. Biomed Rep, 2018, 8(4): 314-318.
38.	Barnes PJ, Anderson GP, Fagerås M, et al. Chronic lung diseases: prospects for regeneration and repair. Eur Respir Rev, 2021, 30(159): 200213.
39.	Cai Z, Guo H, Qian J, et al. Effects of bone morphogenetic protein 4 on TGF-β1-induced cell proliferation, apoptosis, activation and differentiation in mouse lung fibroblasts via ERK/p38 MAPK signaling pathway. PeerJ, 2022, 10: e13775.
40.	刘胜菲, 李龙, 陈凤, 等. 骨膜蛋白在特发性肺纤维化中的研究进展. 中国呼吸与危重监护杂志, 2023, 22(6): 448-451.
41.	Liu P, Li S, Tang L. Nerve growth factor: a potential therapeutic target for lung diseases. Int J Mol Sci, 2021, 22(17): 9112.

1. Liu Q, Sun D, Wang Y, et al. Use of machine learning models to predict prognosis of combined pulmonary fibrosis and emphysema in a Chinese population. BMC Pulm Med, 2022, 22(1): 327.
2. Lee T S, Jin K N, Lee H W, et al. Interstitial lung abnormalities and the clinical course in patients with COPD. Chest, 2021, 159(1): 128-137.
3. Hoyer N, Thomsen LH, Wille MMW, et al. Increased respiratory morbidity in individuals with interstitial lung abnormalities. BMC Pulm Med, 2020, 20(1): 67.
4. Wong A W, Liang J, Cottin V, et al. Diagnostic features in combined pulmonary fibrosis and emphysema: a systematic review. Ann Am Thorac Soc, 2020, 17(10): 1333-6.
5. Sangani R, Ghio A, Culp S, et al. Combined pulmonary fibrosis emphysema: role of cigarette smoking and pulmonary hypertension in a rural cohort. Int J Chron Obstruct Pulmon Dis, 2021, 16: 1873-1885.
6. Koo BS, Park KY, Lee HJ, et al. Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis. Arthritis Res Ther, 2021, 23(1): 100.
7. Nemoto M, Nei Y, Bartholmai B, et al. Automated computed tomography quantification of fibrosis predicts prognosis in combined pulmonary fibrosis and emphysema in a real-world setting: a single-centre, retrospective study. Respir Res, 2020, 21(1): 275.
8. Lee J H, Park H J, Kim S, et al. Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study. BMC Pulm Med, 2023, 23(1): 54.
9. Lee S H, Park J S, Kim S Y, et al. Clinical features and prognosis of patients with idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis, 2019, 23(6): 678-684.
10. 赵倩, 范亚丽, 马瑞敏, 等. 矽肺合并慢性阻塞性肺疾病患病率和危险因素分析. 中华劳动卫生职业病杂志, 2022, 40(8): 602-606.
11. 石蕊, 刘红梅, 孙志谦, 等. 矽肺并发慢性阻塞性肺疾病的回顾性分析. 中华劳动卫生职业病杂志, 2021, 39(8): 590-593.
12. Jacob J, Odink A, Brun A L, et al. Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis. Respir Med, 2018, 138: 95-101.
13. Li L, Yang D C, Chen C H. Metabolic reprogramming: a driver of cigarette smoke-induced inflammatory lung diseases. Free Radic Biol Med, 2021, 163: 392-401.
14. Cottin V, Selman M, Inoue Y, et al. Syndrome of combined pulmonary fibrosis and emphysema: an official ATS/ERS/JRS/ALAT Research Statement. Am J Respir Crit Care Med, 2022, 206(4): e7-e41.
15. Sack CS, Doney BC, Podolanczuk AJ, et al. Occupational exposures and subclinical interstitial lung disease. The MESA (Multi-Ethnic Study of Atherosclerosis) Air and Lung Studies. Am J Respir Crit Care Med, 2017, 196(8): 1031-1039.
16. Arimura-Omori M, Kiyohara C, Yanagihara T, et al. Association between telomere-related polymorphisms and the risk of IPF and COPD as a precursor lesion of lung cancer: findings from the Fukuoka Tobacco-Related Lung Disease (FOLD) Registry. Asian Pac J Cancer Prev, 2020, 21(3): 667-673.
17. Guzmán-Vargas J, Ambrocio-Ortiz E, Pérez-Rubio G, et al. Differential genomic profile in TERT, DSP, and FAM13A between COPD patients with emphysema, IPF, and CPFE syndrome. Front Med (Lausanne), 2021, 8: 725144.
18. Ghosh AJ, Hobbs BD, Yun JH, et al. Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Respir Res, 2022, 23(1): 97.
19. Avci E, Sarvari P, Savai R, et al. Epigenetic mechanisms in parenchymal lung diseases: bystanders or therapeutic targets?. Int J Mol Sci, 2022, 23(1): 546.
20. Soni DK, Biswas R. Role of non-coding RNAs in post-transcriptional regulation of lung diseases. Front Genet, 2021, 12: 767348.
21. Kaur G, Maremanda KP, Campos M, et al. Distinct exosomal miRNA profiles from balf and lung tissue of COPD and IPF Patients. Int J Mol Sci, 2021, 22(21): 11830.
22. Aghali A, Koloko Ngassie ML, Pabelick CM, et al. Cellular senescence in aging lungs and diseases. Cells, 2022, 11(11): 1781.
23. Ortiz-Zapater E, Signes-Costa J, Montero P, et al. Lung fibrosis and fibrosis in the lungs: is it all about myofibroblasts?. Biomedicines, 2022, 10(6).
24. Nemoto MMD, Koo CWMD, Ryu JHMD. Diagnosis and treatment of combined pulmonary fibrosis and emphysema in 2022. JAMA, 2022, 328(1): 69-70.
25. Ogata-Suetsugu S, Hamada N, Tsuda T, et al. Characteristics of tobacco-related lung diseases in Fukuoka Prefecture, Japan: a prospective, multi-institutional, observational study. Respir Investig, 2020, 58(1): 74-80.
26. Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med, 2011, 364(10): 897-906.
27. Özmen İ, Yıldırım E, Öztürk M, et al. Pulmonary rehabilitation reduces emergency admission and hospitalization rates of patients with chronic respiratory diseases. Turk Thorac J, 2018, 19(4): 170-175.
28. Rochester CL, Alison JA, Carlin B, et al. Pulmonary rehabilitation for adults with chronic respiratory disease: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med, 2023, 208(4): e7-e26.
29. Zhang L, Maitinuer A, Lian Z, et al. Home based pulmonary tele-rehabilitation under telemedicine system for COPD: a cohort study. BMC Pulm Med, 2022, 22(1): 284.
30. Tomioka H, Mamesaya N, Yamashita S, et al. Combined pulmonary fibrosis and emphysema: effect of pulmonary rehabilitation in comparison with chronic obstructive pulmonary disease. BMJ Open Respir Res, 2016, 3(1): e000099.
31. Dong F, Zhang Y, Chi F, et al. Clinical efficacy and safety of ICS/LABA in patients with combined idiopathic pulmonary fibrosis and emphysema. Int J Clin Exp Med, 2015, 8(6): 8617-8625.
32. Choi JY, Song JW, Rhee CK. Chronic obstructive pulmonary disease combined with interstitial lung disease. Tuberc Respir Dis (Seoul), 2022, 85(2): 122-136.
33. 宋庆, 林铃, 李雪杉, 等. 慢性阻塞性肺疾病与干细胞的研究进展. 中国呼吸与危重监护杂志, 2022, 21(10): 745-750.
34. Huleihel L, Levine M, Rojas M. The potential of cell-based therapy in lung diseases. Expert Opin Biol Ther, 2013, 13(10): 1429-1440.
35. Cruz FF, Rocco PRM. The potential of mesenchymal stem cell therapy for chronic lung disease. Expert Rev Respir Med, 2020, 14(1): 31-39.
36. Antunes MA, Abreu SC, Cruz FF, et al. Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema. Respir Res, 2014, 15(1): 118.
37. Antoniou KM, Karagiannis K, Tsitoura E, et al. Clinical applications of mesenchymal stem cells in chronic lung diseases. Biomed Rep, 2018, 8(4): 314-318.
38. Barnes PJ, Anderson GP, Fagerås M, et al. Chronic lung diseases: prospects for regeneration and repair. Eur Respir Rev, 2021, 30(159): 200213.
39. Cai Z, Guo H, Qian J, et al. Effects of bone morphogenetic protein 4 on TGF-β1-induced cell proliferation, apoptosis, activation and differentiation in mouse lung fibroblasts via ERK/p38 MAPK signaling pathway. PeerJ, 2022, 10: e13775.
40. 刘胜菲, 李龙, 陈凤, 等. 骨膜蛋白在特发性肺纤维化中的研究进展. 中国呼吸与危重监护杂志, 2023, 22(6): 448-451.
41. Liu P, Li S, Tang L. Nerve growth factor: a potential therapeutic target for lung diseases. Int J Mol Sci, 2021, 22(17): 9112.

Chinese Journal of Respiratory and Critical Care Medicine

Latest Articles间质性肺疾病合并慢性阻塞性肺疾病的研究进展

Abstract Full text Figures/Tables Video References Cited by

Format

Content